Abivax S.A. (ABVX) Stock Analysis & Winston Score
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX
Winston Score: 42/100 — Average
Mixed quality — meaningful strengths and weaknesses.
- Quality: Good (20/30)
- Growth: Mixed (5/20)
- Cash Flow: Weak (0/10)
- Stability: Good (5/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
Key Facts
Price: $136.65
Market Cap: $10.0B
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
